WebMar 16, 2024 · BOSTON -- (BUSINESS WIRE)--Mar. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of … WebInaxaplin (VX-147) is an apolipoprotein L1 (APOL1) function inhibitor (WO2024131807, compound 2). Size Price Stock Qty; 5 mg $765.00. In stock 10 mg In stock Customer Reviews. Based on customer reviews. Add to Cart Bulk Inquiry Free samples from featured products. Tel ...
Vertex Announces Publication in New England Journal of …
WebApr 10, 2024 · APOL1-Mediated Kidney Disease •Based on positive Phase 2 data for inaxaplin (formerly known as VX-147), our small molecule for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, we initiated pivotal development of inaxaplin in a single Phase 2/3 study in patients with two APOL1 mutations and … WebJun 8, 2024 · BOSTON-- ( BUSINESS WIRE )-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and the European Medicines Agency (EMA) has granted … dgc qwertyuiop
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough …
WebJun 8, 2024 · Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) June 8, 2024, 12:00 PM UTC … WebMar 17, 2024 · The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percent change from baseline in proteinuria, in the inaxaplin arm versus placebo. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX 147 in the U.S. for patients with AMKD. WebMar 22, 2024 · “VX-147 holds the potential to be a first-in-class and best-in-class treatment for patients with AMKD, based upon Phase 2 results demonstrating a 47.6% reduction in … cibc bancroft